127 related articles for article (PubMed ID: 36245654)
1. Critical Role of Osteopontin in Maintaining Urinary Phosphate Solubility in CKD.
Stubbs JR; Zhang S; Jansson KP; Fields TA; Boulanger J; Liu S; Rowe PS
Kidney360; 2022 Sep; 3(9):1578-1589. PubMed ID: 36245654
[TBL] [Abstract][Full Text] [Related]
2. Impaired urinary osteopontin excretion in Npt2a-/- mice.
Caballero D; Li Y; Ponsetto J; Zhu C; Bergwitz C
Am J Physiol Renal Physiol; 2017 Jan; 312(1):F77-F83. PubMed ID: 27784695
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin Regulates Phosphate Solubility to Prevent Mineral Aggregates in CKD.
Imig JD
Kidney360; 2022 Sep; 3(9):1477-1479. PubMed ID: 36245661
[No Abstract] [Full Text] [Related]
4. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both.
Mo L; Liaw L; Evan AP; Sommer AJ; Lieske JC; Wu XR
Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1935-43. PubMed ID: 17898038
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification.
Paloian NJ; Leaf EM; Giachelli CM
Kidney Int; 2016 May; 89(5):1027-1036. PubMed ID: 27083280
[TBL] [Abstract][Full Text] [Related]
6. Vascular, valvular and kidney calcification manifested in mouse models of adenine-induced chronic kidney disease.
Yang X; Liu Y; Zhu X; Chen P; Xie X; Xu T; Zhang X; Zhao Y
Ren Fail; 2023 Dec; 45(1):2228920. PubMed ID: 37369635
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin deficiency reduces kidney damage from hypercholesterolemia in Apolipoprotein E-deficient mice.
Pei Z; Okura T; Nagao T; Enomoto D; Kukida M; Tanino A; Miyoshi K; Kurata M; Higaki J
Sci Rep; 2016 Jun; 6():28882. PubMed ID: 27353458
[TBL] [Abstract][Full Text] [Related]
8. Microscopic nephrocalcinosis in chronic kidney disease patients.
Evenepoel P; Daenen K; Bammens B; Claes K; Meijers B; Naesens M; Sprangers B; Kuypers D; Lerut E
Nephrol Dial Transplant; 2015 May; 30(5):843-8. PubMed ID: 25586405
[TBL] [Abstract][Full Text] [Related]
9. Role of osteopontin in early phase of renal crystal formation: immunohistochemical and microstructural comparisons with osteopontin knock-out mice.
Hirose M; Tozawa K; Okada A; Hamamoto S; Higashibata Y; Gao B; Hayashi Y; Shimizu H; Kubota Y; Yasui T; Kohri K
Urol Res; 2012 Apr; 40(2):121-9. PubMed ID: 21833789
[TBL] [Abstract][Full Text] [Related]
10. Immuno-localization of CD44 and osteopontin in developing human kidney.
Crisi GM; Marconi SA; Rockwell GF; Braden GL; Campfield TJ
Pediatr Res; 2009 Jan; 65(1):79-84. PubMed ID: 18787423
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin as a Biomarker in Chronic Kidney Disease.
Sinha SK; Mellody M; Carpio MB; Damoiseaux R; Nicholas SB
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239027
[TBL] [Abstract][Full Text] [Related]
12. Dentoalveolar Alterations in an Adenine-Induced Chronic Kidney Disease Mouse Model.
Mohamed FF; Amadeu de Oliveira F; Kinoshita Y; Yalamanchili RR; Eltilib LA; Andras NL; Narisawa S; Tani T; Chu EY; Millán JL; Foster BL
J Bone Miner Res; 2023 Aug; 38(8):1192-1207. PubMed ID: 37191192
[TBL] [Abstract][Full Text] [Related]
13. Nephrocalcinosis in animal models with and without stones.
Khan SR
Urol Res; 2010 Dec; 38(6):429-38. PubMed ID: 20658131
[TBL] [Abstract][Full Text] [Related]
14. Modulation of calcium oxalate dihydrate growth by phosphorylated osteopontin peptides.
Chien YC; Mansouri A; Jiang W; Khan SR; Gray JJ; McKee MD
J Struct Biol; 2018 Nov; 204(2):131-144. PubMed ID: 30016645
[TBL] [Abstract][Full Text] [Related]
15. Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice.
Yuan Q; Jiang Y; Zhao X; Sato T; Densmore M; Schüler C; Erben RG; McKee MD; Lanske B
J Bone Miner Res; 2014 Mar; 29(3):693-704. PubMed ID: 24038141
[TBL] [Abstract][Full Text] [Related]
16. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro.
Sage AP; Lu J; Tintut Y; Demer LL
Kidney Int; 2011 Feb; 79(4):414-22. PubMed ID: 20944546
[TBL] [Abstract][Full Text] [Related]
18. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice Partially Rescues the Deficient Mineralization Without Correcting Hypophosphatemia.
Hoac B; Østergaard M; Wittig NK; Boukpessi T; Buss DJ; Chaussain C; Birkedal H; Murshed M; McKee MD
J Bone Miner Res; 2020 Oct; 35(10):2032-2048. PubMed ID: 32501585
[TBL] [Abstract][Full Text] [Related]
19. β-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis.
Chen S; Zhang M; Li J; Huang J; Zhou S; Hou X; Ye H; Liu X; Xiang S; Shen W; Miao J; Hou FF; Liu Y; Zhou L
J Extracell Vesicles; 2022 Mar; 11(3):e12203. PubMed ID: 35312232
[TBL] [Abstract][Full Text] [Related]
20. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion.
Persy VP; Verstrepen WA; Ysebaert DK; De Greef KE; De Broe ME
Kidney Int; 1999 Aug; 56(2):601-11. PubMed ID: 10432399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
